Recent News

• 03.31.2026 - Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
• 03.12.2026 - Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
• 03.02.2026 - Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
• 02.24.2026 - Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement
• 01.12.2026 - Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor
• 12.30.2025 - Cadrenal’s Pipeline Looks Less Like a Microcap and More Like an Emergency Response System
• 12.29.2025 - Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On
• 12.17.2025 - Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Recent Filings

• 03.12.2026 - 8-K Current report
• 03.12.2026 - EX-99.1 EX-99.1
• 02.24.2026 - EX-99.1 EX-99.1
• 02.24.2026 - 8-K Current report
• 01.02.2026 - 424B3 Prospectus [Rule 424(b)(3)]
• 12.31.2025 - EFFECT Notice of Effectiveness
• 12.31.2025 - D Notice of Exempt Offering of Securities
• 12.31.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.29.2025 - 144 Report of proposed sale of securities
• 12.29.2025 - S-1 General form for registration of securities under the Securities Act of 1933